0001179110-20-000564.txt : 20200114
0001179110-20-000564.hdr.sgml : 20200114
20200114184845
ACCESSION NUMBER: 0001179110-20-000564
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200110
FILED AS OF DATE: 20200114
DATE AS OF CHANGE: 20200114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fletcher Robert C.
CENTRAL INDEX KEY: 0001508231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31918
FILM NUMBER: 20527006
MAIL ADDRESS:
STREET 1: 730 STOCKTON DRIVE
CITY: EXTON
STATE: PA
ZIP: 19341
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDERA PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000861838
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 043072298
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 EAGLEVIEW BOULEVARD
STREET 2: SUITE 212
CITY: EXTON
STATE: PA
ZIP: 19341
BUSINESS PHONE: 4843481600
MAIL ADDRESS:
STREET 1: 505 EAGLEVIEW BOULEVARD
STREET 2: SUITE 212
CITY: EXTON
STATE: PA
ZIP: 19341
FORMER COMPANY:
FORMER CONFORMED NAME: HYBRIDON INC
DATE OF NAME CHANGE: 19951211
4
1
edgar.xml
FORM 4 -
X0306
4
2020-01-10
0
0000861838
IDERA PHARMACEUTICALS, INC.
IDRA
0001508231
Fletcher Robert C.
C/O IDERA PHARMACEUTICALS, INC.
505 EAGLEVIEW BLVD., SUITE 212
EXTON
PA
19341
0
1
0
0
Sr. VP, Bus. Dev. & Strategy
Common Stock
2020-01-10
4
A
0
20000
0
A
36485
D
Stock Option (Right to Buy)
1.79
2020-01-10
4
A
0
50000
0
A
2030-01-10
Common Stock
50000
50000
D
Represents a restricted stock unit ("RSU") award granted under the Issuer's 2013 Stock Incentive Plan. Each RSU represents a right to receive one share of Issuer common stock. The RSU award vests over a four-year period commencing on January 10, 2020. Twenty-five percent (25%) of the shares subject to the RSU award shall vest on each one-year anniversary of the grant date of the award.
Securities beneficially owned totaling 36,485 includes 2,910 shares of Issuer common stock owned and 33,575 of unvested RSU's held by the reporting person.
The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 10, 2020. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 10, 2021 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.
/s/ Robert Clayton Fletcher
2020-01-14